We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Therapy Cures Heart Disorder in Mouse Model

By Biotechdaily staff writers
Posted on 23 Aug 2006
Researchers have identified a subtype of the adeno-associated virus (AAV) that is 200 times more potent in its ability to penetrate cardiac tissue, and have demonstrated its potential for use in gene therapy by successfully treating a mouse model for Pompe disease. More...


Pompe disease (also called glycogen storage disease type II or acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA), which is needed to break down glycogen. It is the only glycogen storage disease with a defect in lysosomal metabolism and was the first glycogen storage disease to be identified.

The build-up of glycogen causes progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and nervous system. Transmission is by autosomal recessive inheritance. Children have a one in four chance of inheriting the disease when both parents carry the abnormal gene. It is estimated to occur in about one in 40,000-300,000 births.

Investigators at the University of Florida (Gainesville, USA) evaluated several different sub-types of AAV as potential vectors for gene therapy of congenital heart diseases. They found that the AAV-9 subtype was taken up throughout the heart muscle at 200 times the levels achieved with the previously used AAV-1 subtype. None of the AAV subtypes tested were found to cause disease or trigger a major immune system reaction.

The AAV-9 vector was loaded with the gene for GGA that is lacking in Pompe disease and then injected into animals in a mouse model for the syndrome. Results published in the July 27, 2006, online edition of Circulation Research revealed that the gene therapy eliminated symptoms of the disease.

"Right now AAV-9 seems to be our best solution for heart problems,” said senior author Dr. Barry J. Byrne, professor of pediatric cardiology at the University of Florida. "This is a way of delivering gene therapy to the heart that is aimed at treating genetic diseases affecting the heart. It is efficient and long lasting. One of the other distinguishing features of our research is that it is probably the first to demonstrate a physiologic correction of a genetic cardiac abnormality.”



Related Links:
University of Florida

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

New Insights Into Fetal DNA Could Improve Non-Invasive Prenatal Testing

Non-invasive prenatal testing is widely used to screen pregnancies for genetic conditions by analyzing DNA fragments in maternal blood. Although it offers a safer alternative to invasive procedures such... Read more

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.